We have since initiated over 15 discovery projects since the inception of Regor in June 2018. Our projects cover oncology, autoimmune and metabolic diseases areas with a strategy balance of Best-In-Class and First-In-Class programs. By fully leveraging our CARD technology platform, we are able to deliver four PCCs within the range of 10-12 months from the initiation of each program. We have recently initiated IND-enabling studies for the first wave of three Pre-Clinical Candidates (PCC) in 2019 and we are poised to become a clinical stage biotech within this year.

245 Main Street, Second Floor, Cambridge, MA 02142, USA 1206 Zhangjiang Rd, Building C, Pudong New District, Shanghai 201210, China